Dan Dilks Email

SVP Business Development & Commercial . ACCUGENOMICS

Current Roles

Employees:
9
Revenue:
$1.4M
About
AccuGenomics is a developer of a unique spike-in control technology that dramatically improves the accuracy and performance of clinical sequencing tests for low abundance biomarkers such as circulating tumor DNA (ctDNA) and low titer infectious pathogens such as SARS-CoV-2. Standardized Nucleic Acid Quantification for Sequencing (SNAQâ„¢-SEQ) is an innovative QC method that uses mixtures of synthetic DNA or RNA internal standards (MISâ„¢) spiked into each sample prior to NGS library prep. Being mixed with the sample and biochemically identical to the regions of interest, these standards undergo the same processing, handling and reaction conditions as the sample does, to provide the ideal run control approach for NGS-based assays. SNAQ-SEQ spike-in controls provide much higher confidence in the results of sequencing tests, eliminate false positives and dramatically reduce false negatives resulting in better overall accuracy as compared to using external (or no) controls alone.
ACCUGENOMICS Address
1410 COMMONWEALTH DR STE 105
WILMINGTON, NC
ACCUGENOMICS Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.